Immune Checkpoint Inhibitors: Changing the Treatment Landscape in Esophagogastric Adenocarcinoma

In the West, recent decades have demonstrated an epidemiological trend towards esophago-gastric adenocarcinomas (EGAC), with considerable associated mortality. Historically, chemotherapy has represented the sole systemic treatment option in the advanced EGAC setting, in addition to complementing the...

Descripción completa

Detalles Bibliográficos
Autores principales: Lynch, Emer, Duffy, Austin G., Kelly, Ronan J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9865965/
https://www.ncbi.nlm.nih.gov/pubmed/36678598
http://dx.doi.org/10.3390/ph16010102

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9865965/
https://www.ncbi.nlm.nih.gov/pubmed/36678598
http://dx.doi.org/10.3390/ph16010102

Ejemplares similares